Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kezar Life Sciences, Inc.

Get SEC filing alerts via email and in your feed for Kezar Life Sciences, Inc.

KZR

Kezar Life Sciences, Inc.

About Kezar Life Sciences, Inc.

Kezar Life Sciences is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases. Its lead candidate, zetomipzomib, targets the immunoproteasome to treat autoimmune conditions like AIH and lupus. The company aims to offer broad immunomodulation with convenient dosing, leveraging proprietary IP and strategic collaborations to address high unmet medical needs in autoimmune and inflammatory disorders.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kezar Life Sciences, Inc.

1
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports $5.8 Million Net Loss in Q1 2026, Announces Merger with Aurinia Pharma

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports $56M Net Loss for 2025, Implements Restructuring Plan

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports Improved Net Loss of $11.2 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports Improved Net Loss of $13.7 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports $16.6 Million Net Loss in Q1 2025, Decreases Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports $83.7 Million Net Loss for 2024, Down from $101.9 Million in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Kezar Life Sciences, Inc. Kezar Life Sciences Reports Significant Financial Changes, Restructuring, and Clinical Trial Termination in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments